Tyra claims Phase 2 win in bladder cancer, will advance drug to pivotal trial

Tyra Biosciences wants to challenge Johnson & Johnson in a low-risk form of bladder cancer. The Phase 2 data it released Wednesday takes a step toward that goal — although you just might have to squint ...